The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy

European Journal of Endocrinology

Volumn 161, Issue 4, 2009, Pages 541-546

  Adetunji, O R ^a   MacFarlane, I A ^a   Javadpour, M ^b   Alfirevic, A ^c   Pirmohamed, M ^c   Blair, J C ^d  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GROWTH HORMONE RECEPTOR; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY HEIGHT; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; DRUG DOSE TITRATION; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE; ANTHROPOMETRY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANTHROPOMETRY; BODY COMPOSITION; FEMALE; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUALITY OF LIFE; RECEPTORS, SOMATOTROPIN; RECOMBINANT PROTEINS;

EID: 70349757676     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0405     Document Type: Article

References (22)

1. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U & Amselem S. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. Journal of Clinical Endocrinology and Metabolism 2003 88 1705-1710. (Pubitemid 36623392)
2. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V & Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genetics 2004 36 720-724. (Pubitemid 38886633)
3. Toyoshima MT, Castroneves LA, Costalonga EF, Mendonca BB, Arnhold IJ & Jorge AA. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clinical Endocrinology 2007 67 500-504.
4. Carrascosa A, Audi L, Fernandez-Cancio M, Esteban C, Andaluz P, Vilaro E, Clemente M, Yeste D, Albisu MA & Gussinye M. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. Journal of Clinical Endocrinology and Metabolism 2008 93 764-770.
5. Binder G, Baur F, Schweizer R & Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for- gestational-age children. Journal of Clinical Endocrinology and Metabolism 2006 91 659-664. (Pubitemid 43236940)
6. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB & Arnhold IJ. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2006 91 1076-1080.
7. Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD & Buzi F. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. Journal of Clinical Endocrinology and Metabolism 2006 91 1178-1180. (Pubitemid 43357798)
8. Carrascosa A, Esteban C, Espadero R, Fernandez-Cancio M, Andaluz P, Clemente M, Audi L, Wollmann H, Fryklund L & Parodi L. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational- age children: results from a two-year controlled prospective study in 170 Spanish patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3281-3286. (Pubitemid 44402092)
9. Human growth hormone (somatropin) in adults with growth hormone deficiency. Revised July 2006. August 2003: National Institute for Clinical Excellence.
10. Leong KS, Walker AB, Martin I, Wile D, Wilding J & MacFarlane IA. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clinical Endocrinology 2001 54 463-468. (Pubitemid 34204182)
11. Gomez JM, Espadero RM, Escobar-Jimenez F, Hawkins F, Pico A, Herrera-Pombo JL, Vilardell E, Duran A, Mesa J, Faure E & Sanmarti A. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clinical Endocrinology 2002 56 329-334. (Pubitemid 34310010)
12. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wiren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383. (Pubitemid 29369642)
13. Wallymahmed ME, Baker GA, Humphris G, Dewey M & MacFarlane IA. The development, reliability and validity of a disease specific quality of lifemodel for adults with growth hormone deficiency. Clinical Endocrinology 1996 44 403-411. (Pubitemid 26141685)
14. Malik IA, Foy P, Wallymahmed M, Wilding JP & MacFarlane IA. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clinical Endocrinology 2003 59 75-81. (Pubitemid 36774111)
15. Growth hormone deficiency (adults) - human growth hormone. In: Technical Appraisal 64. August 2003: National Institute for Clinical Excellence.
16. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M & Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. Journal of Biological Chemistry 2000 275 18664-18669.
17. van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW & Romijn JA. Influence of the d3-growth hormone receptor isoform on short-term and long-term treatment response to growth hormone replacement in growth hormone deficient adults. Journal of Clinical Endocrinology and Metabolism 2008 93 2828-2834. (Pubitemid 352008558)
18. Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH & MacFarlane IA. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clinical Endocrinology 1997 47 439-446. (Pubitemid 27452063)
19. Deepak D, Furlong NJ, Wilding JP & MacFarlane IA. Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. Postgraduate Medical Journal 2007 83 277-280. (Pubitemid 46663016)
20. Carroll PV, Christ ER & Sonksen PH. Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge. Trends in Endocrinology and Metabolism 2000 11 231-238. (Pubitemid 30603170)
21. Audi L, Esteban C, Carrascosa A, Espadero R, Perez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L & Parodi LA. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n=247) and in an adult control population (n=289) show increased fl/fl in short SGA. Journal of Clinical Endocrinology and Metabolism 2006 91 5038-5043.
22. Wan L, Chen WC, Tsai Y, Kao YT, Hsieh YY, Lee CC, Tsai CH, Chen CP & Tsai FJ. Growth hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency. Pediatric Research 2007 62 735-740. (Pubitemid 350158816)